{
    "body": "Is apixaban effective for treatment of acute venous thromboembolism?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/18393142", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24554904", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23117646", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22153026", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24057162", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23808982", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22084658", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19014462", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22795419", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23233582", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19308891", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24278706", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23822763", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23150473"
    ], 
    "ideal_answer": [
        "Apixaban is a direct inhibitor of factor Xa, and is a potential alternative for the treatment of acute venous thromboembolism. These results suggest a lack of clear superiority of apixaban relative to enoxaparin. Apixaban is an oral alternative with similar efficacy and safety to existing anticoagulant therapies.", 
        "Yes, apixaban is effective for treatment of acute venous thromboembolismis. Apixiban is a direct inhibitor of factor Xa, and is a potential alternative for the treatment of acute venous thromboembolism. Apixaban is an oral alternative with similar efficacy and safety to existing anticoagulant therapies."
    ], 
    "exact_answer": "yes", 
    "concepts": [
        "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013923", 
        "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013812", 
        "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020246", 
        "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D054556", 
        "http://www.biosemantics.org/jochem#4243936"
    ], 
    "type": "yesno", 
    "id": "52fc94572059c6d71c000070", 
    "snippets": [
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 127, 
            "text": "Apixaban is a direct inhibitor of factor Xa, and is a potential alternative for the treatment of acute venous thromboembolism. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24057162", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 945, 
            "offsetInEndSection": 1132, 
            "text": "These results suggest a lack of clear superiority of apixaban relative to enoxaparin. Apixaban is an oral alternative with similar efficacy and safety to existing anticoagulant therapies.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24057162", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1718, 
            "offsetInEndSection": 1898, 
            "text": "A fixed-dose regimen of apixaban alone was noninferior to conventional therapy for the treatment of acute venous thromboembolism and was associated with significantly less bleeding", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23808982", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 11, 
            "offsetInEndSection": 186, 
            "text": "To critically review the effectiveness of the novel oral anticoagulants (rivaroxaban, dabigatran, ximelagatran, and apixaban) in the treatment of acute venous thromboembolism.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23150473", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 2087, 
            "offsetInEndSection": 2308, 
            "text": "ompared with vitamin K antagonists, the novel oral anticoagulants had a similar risk of recurrence of acute venous thromboembolism and all cause mortality, though rivaroxaban was associated with a reduced risk of bleeding", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23150473", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 103, 
            "offsetInEndSection": 329, 
            "text": "Nowadays, the new anticoagulants, such as dabigatran, rivaroxaban and apixaban, show potential advantages over classical treatments. These agents inhibit specific coagulation factors and are administered orally at fixed doses.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23117646", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1192, 
            "offsetInEndSection": 1308, 
            "text": "In a recently completed phase III trial, apixaban also demonstrated promising efficacy and safety in that indication", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22795419", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 318, 
            "offsetInEndSection": 419, 
            "text": "the most advanced oral direct inhibitors to factor Xa (rivaroxaban and apixaban) and IIa (dabigatran)", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/18393142", 
            "endSection": "abstract"
        }
    ]
}